Dyslipidemia News and Research RSS Feed - Dyslipidemia News and Research

Dyslipidemia is a disruption in the amount of lipids in the blood.
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
New research identifies five medical conditions that contribute to more North Carolina SUD cases

New research identifies five medical conditions that contribute to more North Carolina SUD cases

Sudden unexpected death (SUD) results from a malfunction of the heart and causes a rapid loss of blood flow through the body, leading to death. It is a very rapid process and may have few or no known warning signs. The overall survival rate for out-of-hospital arrest is only 5-10%. SUD is responsible for upwards of 450,000 people in the United States each year, with North Carolina experiencing an average of 32 SUD-related deaths each day. [More]
Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol. [More]
Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy. [More]
Tree nuts have positive impact on glycemic control in diabetes and on metabolic syndrome criteria

Tree nuts have positive impact on glycemic control in diabetes and on metabolic syndrome criteria

Two new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) were recently published in the online publications, British Medical Journal Open (BMJ Open) and PLOS ONE. [More]
Rates of stroke incidence, subsequent death decrease among black and white U.S. adults

Rates of stroke incidence, subsequent death decrease among black and white U.S. adults

In a study that included a large sample of black and white U.S. adults from several communities, rates of stroke incidence and subsequent death decreased from 1987 to 2011, with decreases varying across age-groups, according to a study in the July 16 issue of JAMA. [More]
Study reveals mechanism underlying abnormal fat accumulation in HIV patients

Study reveals mechanism underlying abnormal fat accumulation in HIV patients

Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs -small RNA molecules that play important roles in regulation in many types of tissue - play a major role in the distribution and determination of fat cells and whole body metabolism. [More]
Study calls for more proactive approach towards complete dyslipidemia diagnosis in clinical practice

Study calls for more proactive approach towards complete dyslipidemia diagnosis in clinical practice

Clinical inertia does not allow healthcare professionals to diagnose cholesterol problems in the 65.3% of cases. The results warn of the need to adopt a more proactive attitude towards a complete dyslipidemia diagnosis in routine clinical practice, especially if it is taken into account that it is an illness related to an increase of cardiovascular risk. [More]
Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors. [More]
Weight loss most important factor for improving cardiovascular health in obese OSA patients

Weight loss most important factor for improving cardiovascular health in obese OSA patients

Obesity and obstructive sleep apnea (OSA) tend to co-exist and are associated with a variety of cardiovascular risk factors, including inflammation, insulin resistance, abnormal cholesterol, and high blood pressure. While effective therapies are available for OSA, researchers are still unclear about what interventions are most effective in reducing the burden of risk factors for cardiovascular disease associated with OSA in obese patients. [More]
Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

The International Society for Autism Research (INSAR), a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders, convened more than 1700 researchers, delegates, autism specialists and students from 40 countries for the 13th Annual International Meeting for Autism Research (IMFAR), the world's largest scientific gathering on autism research, from May 15 through May 17 at the Atlanta Marriott Marquis in Atlanta, GA. [More]
Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates. [More]
AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). [More]
Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes. [More]
Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva announces publication of LAL Deficiency review in Atherosclerosis

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare diseases, today announced the publication of an overview of lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Atherosclerosis, the official journal of the European Atherosclerosis Society. [More]
Measurement of calcium in coronary arteries can predict heart disease risk

Measurement of calcium in coronary arteries can predict heart disease risk

With growing evidence that a measurement of the buildup of calcium in coronary arteries can predict heart disease risk, Los Angeles Biomedical Research Institute (LA BioMed) researchers found that the process of "calcium scoring" was also accurate in predicting the chances of dying of heart disease among adults with little or no known risk of heart disease. [More]
Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Mayo Clinic research shows RA patients more likely to develop chronic kidney disease

Rheumatoid arthritis patients are likelier than the average person to develop chronic kidney disease, and more severe inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]